Clinical Trial Update: Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation [Phase 1]

View source ↗

Summary

This Clinical Trial Update reports safety and pharmacokinetic results from a Phase 1 study of N6022 in cystic fibrosis patients homozygous for the F508del-CFTR …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• N6022

Snippet

Sponsor: Nivalis Therapeutics, Inc. | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED | Results posted: 2014-11-24